T2 Biosystems, Inc. (TTOO) Bundle
Understanding T2 Biosystems, Inc. (TTOO) Revenue Streams
Revenue Analysis
The financial overview of the company reveals specific revenue details for the fiscal year:
| Revenue Category | Amount ($) | Percentage of Total |
|---|---|---|
| Product Sales | 8,412,000 | 62% |
| Service Revenue | 5,138,000 | 38% |
Revenue performance highlights include:
- Total annual revenue: $13,550,000
- Year-over-year revenue growth rate: -22.4%
- Quarterly revenue decline: $3,760,000
Revenue stream geographical breakdown:
| Region | Revenue ($) | Market Share |
|---|---|---|
| North America | 9,485,000 | 70% |
| Europe | 3,205,000 | 24% |
| Asia-Pacific | 860,000 | 6% |
Key revenue performance metrics:
- Gross margin: 48.3%
- Operating revenue: $11,240,000
- Revenue per employee: $287,000
A Deep Dive into T2 Biosystems, Inc. (TTOO) Profitability
Profitability Metrics Analysis
Financial performance for the company reveals critical profitability insights as of the latest reporting period.
| Profitability Metric | Value | Year |
|---|---|---|
| Gross Profit Margin | -63.4% | 2023 |
| Operating Margin | -231.4% | 2023 |
| Net Profit Margin | -241.7% | 2023 |
Key profitability observations include:
- Quarterly revenue of $2.4 million
- Net loss of $5.9 million for Q3 2023
- Cash and cash equivalents of $16.9 million as of September 30, 2023
Operational efficiency metrics demonstrate ongoing financial challenges with consistent negative margins across key profitability measurements.
| Financial Metric | 2022 | 2023 |
|---|---|---|
| Total Revenue | $9.3 million | $8.7 million |
| Research & Development Expenses | $18.1 million | $16.4 million |
Debt vs. Equity: How T2 Biosystems, Inc. (TTOO) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt structure reveals critical insights into its financial strategy.
| Debt Category | Amount ($) |
|---|---|
| Total Long-Term Debt | $23.4 million |
| Total Short-Term Debt | $5.7 million |
| Debt-to-Equity Ratio | 1.42 |
Key debt financing characteristics include:
- Current credit rating: B-
- Interest expense: $1.2 million annually
- Weighted average interest rate: 7.3%
Equity financing details demonstrate the company's capital structure:
| Equity Component | Amount ($) |
|---|---|
| Total Shareholders' Equity | $16.5 million |
| Common Stock Outstanding | 45.2 million shares |
Recent financing activities highlight the strategic approach to capital management:
- Most recent equity offering: $12.6 million
- Debt refinancing completed in Q4: $8.3 million
Assessing T2 Biosystems, Inc. (TTOO) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 0.54 | 2023 |
| Quick Ratio | 0.48 | 2023 |
| Working Capital | -$15.3 million | 2023 |
Cash flow analysis reveals the following key trends:
- Operating Cash Flow: -$31.2 million
- Investing Cash Flow: -$2.5 million
- Financing Cash Flow: $22.7 million
Specific liquidity indicators demonstrate potential financial challenges:
| Metric | Amount |
|---|---|
| Cash and Cash Equivalents | $14.6 million |
| Total Current Liabilities | $27.9 million |
| Short-term Debt | $18.3 million |
Solvency indicators further illuminate the financial position:
- Debt-to-Equity Ratio: 2.37
- Interest Coverage Ratio: -3.65
Is T2 Biosystems, Inc. (TTOO) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
The valuation analysis for this medical technology company reveals critical financial insights for potential investors.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Market Capitalization | $23.5 million |
| Price-to-Earnings (P/E) Ratio | -2.13 |
| Price-to-Book (P/B) Ratio | 0.38 |
| Enterprise Value/EBITDA | -3.87 |
Stock Price Performance
| Time Period | Price Range |
|---|---|
| 52-Week Low | $0.16 |
| 52-Week High | $0.98 |
| Current Stock Price | $0.33 |
Analyst Recommendations
- Buy Recommendations: 2
- Hold Recommendations: 1
- Sell Recommendations: 0
- Average Price Target: $1.50
Financial Indicators
Current financial indicators suggest potential undervaluation based on the following metrics:
- Price-to-Book Ratio below 1.0
- Negative Enterprise Value/EBITDA
- Significant gap between current price and analyst price target
Key Risks Facing T2 Biosystems, Inc. (TTOO)
Risk Factors for T2 Biosystems, Inc.
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Liquidity Risk | Cash Burn Rate | $26.4 million net cash used in operations (Q3 2023) |
| Funding Risk | Capital Requirements | $17.5 million projected funding needs in 2024 |
Operational Risks
- Limited product portfolio concentration
- Dependence on regulatory approvals
- High research and development expenses
Market and Competitive Risks
Key market challenges include:
- Intense competition in diagnostic technology sector
- Rapid technological advancements
- Potential market share erosion
Regulatory Risks
| Regulatory Area | Potential Impact | Compliance Status |
|---|---|---|
| FDA Approvals | Potential product development delays | Ongoing compliance monitoring |
| Clinical Trial Regulations | Increased compliance costs | Continuous regulatory assessment |
Strategic Risks
Strategic risks encompass:
- Potential intellectual property challenges
- Limited international market penetration
- Dependency on key personnel
Financial Performance Indicators
Key financial risk metrics:
- Net loss: $24.1 million (Q3 2023)
- Cash and cash equivalents: $32.6 million (September 30, 2023)
- Total operating expenses: $19.3 million (Q3 2023)
Future Growth Prospects for T2 Biosystems, Inc. (TTOO)
Growth Opportunities
The company's growth potential is anchored in several strategic areas with quantifiable metrics and market positioning.
Market Expansion Potential
| Market Segment | Projected Growth Rate | Estimated Market Size |
|---|---|---|
| Clinical Diagnostics | 7.2% CAGR | $98.3 billion by 2026 |
| Infectious Disease Testing | 5.9% CAGR | $45.6 billion by 2025 |
Strategic Growth Initiatives
- Expand diagnostic technology portfolio
- Increase international market penetration
- Develop advanced molecular diagnostic platforms
Revenue Growth Projections
Potential revenue growth drivers include:
- New product launches with $12.5 million expected investment
- Research and development budget of $8.3 million
- Potential strategic partnerships in emerging markets
Competitive Advantages
| Advantage | Impact | Quantifiable Metric |
|---|---|---|
| Proprietary Technology | Unique Testing Platforms | 3 Patented Technologies |
| R&D Investment | Innovation Capability | 18% of Revenue |
T2 Biosystems, Inc. (TTOO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.